Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2025, Fortress Biotech, Inc. reported revenue of $63M, up 9.7% year over year. Operating margin was -111.0% and net margin 10.8%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from FBIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $63M | -111.0% | 10.8% |
| FY2024 | $58M | -191.4% | -79.8% |
| FY2023 | $85M | -168.4% | -71.7% |
| FY2022 | $76M | -268.8% | -114.3% |
| FY2021 | $69M | -274.1% | -94.1% |
How does FBIO compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.